摘要
克力芝(洛匹那韦/利托那韦复方制剂)对于治疗新型冠状病毒肺炎具有潜在疗效,该文对该药物的专利布局态势进行分析,反映药物全球专利布局格局,揭示我国在该药物研发上的专利布局特点和壁垒,为我国药物研发攻关以及宏观决策提供支撑。该文利用专利数据,基于专利计量分析方法,从克力芝专利布局时间分布、逐年专利布局技术方向、逐年专利申请国家分布、各国专利技术布局方向分析、专利申请人分析几个角度展示了克力芝的专利布局态势。研究发现克力芝的专利布局日趋成熟,近年来的技术布局主要围绕制剂、新用途和制备工艺,美国艾伯维公司及其拆分前母公司雅培公司是相关专利的主要持有者,我国的专利布局主要围绕该药物的制备工艺和新用途,基础化合物专利布局较弱。
Kaletra,the compound of Lopinavir and Ritonavir,has a potential therapeutic effect on COVID-19.To provide support for drug research and development in China and macro decision making,this paper analyzes the patent portfolio of Kaletra,reflects the global patent application trend,reveals the patent barriers faced by our country in the research and development of the drug.Based on the patent data and the method of patent bibliometrics,this paper shows the patent portfolio of Kaletra from the following aspects:time distribution of patent application,technology direction of patent application year by year,country distribution of patent application year by year,technology direction of patent application in various countries and patent applicant analysis.It is found that the patent portfolio of Coriolis is becoming more and more mature.In recent years,the direction of patent application mainly focuses on preparations,new uses and preparation processes.Abbvie Inc.and its parent company Abbott are the main holders of related patents.In China,the patent application mainly focuses on the preparation process and new uses of the drug,while the patent application for basic compound is weak.
作者
吕璐成
郑丽丽
赵亚娟
Lyu Lucheng;Zheng Lili;Zhao Yajuan(National Science Library,Chinese Academy of Sciences,Bejing 100190,China)
出处
《科学观察》
2020年第5期45-51,共7页
Science Focus
